Molecular Therapy-Oncolytics

Papers
(The median citation count of Molecular Therapy-Oncolytics is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Ferroptosis gene signature in cholangiocarcinoma83
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence56
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 155
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis48
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML40
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma37
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers37
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity36
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy36
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer35
PROTACs in gastrointestinal cancers35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer34
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T31
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme30
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy30
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia29
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges28
A library of cancer testis specific T cell receptors for T cell receptor gene therapy27
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia27
Radiovirotherapy at twenty26
Adding recombinant AAVs to the cancer therapeutics mix26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products25
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice24
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum24
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma24
Oncolytic adenovirus for treatment of malignant ascites24
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression23
DNA-damaging cancer cells to improve virotherapy22
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis22
Thank you to our 2023 reviewers22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities22
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?22
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells21
Non-coding RNAs and glioma: Focus on cancer stem cells21
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response21
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers21
Sodium iodide symporter-targeted gene therapy in glioblastoma20
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering20
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon20
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo20
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape20
Exploring the potential of eRNAs in cancer immunotherapy19
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives19
Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution19
Comprehensive landscape of tRNA-derived fragments in lung cancer19
Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy19
Gaining insights into virotherapy with canine models19
Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells18
A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics18
Targeting mesothelin in cancer18
A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase17
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project17
Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer17
Tagmentation-based analysis reveals the clonal behavior of CAR-T cells in association with lentivector integration sites17
The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics16
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer16
miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration16
Advancements in CRISPR screens for the development of cancer immunotherapy strategies15
Retraction Notice to: miR-140-3p Inhibits Cutaneous Melanoma Progression by Disrupting AKT/p70S6K and JNK Pathways through ABHD215
Expanding the landscape of TCR gene therapy targeting MAGE15
Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma15
Oncolytic viruses: Narcissistic or altruistic arsonists?14
Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies14
Attack of the clones: An NK cell origins story14
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer14
Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation14
PTEN potentiation of oncolytic HSV therapy for glioblastoma14
Novel roles of METTL1/WDR4 in tumor via m7G methylation14
An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition13
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions13
A library of cancer testis specific T cell receptors for T cell receptor gene therapy13
Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition13
Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives12
Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors12
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh912
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors12
Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models12
Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody12
Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.212
Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model12
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors11
TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I11
Dynamic fine-tuning of CAR-T cell therapy11
The tRNA-derived fragment signature in lung cancer11
Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma11
0.12025094032288